Blood Journals Portfolio
Jun 21, 2026, 16:12
Cost Savings and Reduced Factor Consumption With Efanesoctocog Alfa – Blood Journals Portfolio
Blood Journals Portfolio shared a post on X about a recent article by Janice M. Staber et al, adding:
”The high-sustained FVIII therapy efanesoctocog alfa resulted in 3 to 5.5 times lower consumption and may save USD 38 947 to USD 81 000 per surgery.
Read the full study in Blood VTH.”
Title: Cost comparison of efanesoctocog alfa vs conventional factor VIII therapies for major surgeries in patients with severe hemophilia A
Authors: Janice M. Staber, Alix Arnaud, Ion Agirrezabal, Duygu Bozkaya, Lane Anson, Andrew Wilson, Nana Kragh, Doris Quon, Allison P. Wheeler
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 11, 2026, 08:20Hasan Abbas Zaheer: Strengthening Universal Access to Safe Blood in Pakistan
-
Aug 11, 2026, 08:07Nicola Pozzi: Advancing Hemostasis Through Scientific Collaboration at Hemostasis GRC
-
Aug 11, 2026, 07:50When Access to Care Changes Everything – WFH
-
Aug 11, 2026, 07:41Kevin Land: How Cellular Therapy Is Changing Transfusion Medicine
-
Aug 11, 2026, 07:35Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
-
Aug 11, 2026, 07:28Archil Jaliashvili: When Every Minute Matters Time Becomes a Therapy
-
Aug 11, 2026, 07:05Mavis Agnes Kisakye: Building Sustainable Transition Pathways in Hemophilia Care
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda